Harrow Launches First Ophthalmology Biosimilar in U.S., Expanding Retina Portfolio
Event summary
- Harrow launched BYOOVIZ® (ranibizumab-nuna), the first FDA-approved ophthalmology biosimilar in the U.S., referencing LUCENTIS.
- BYOOVIZ is interchangeable with LUCENTIS, offering retina specialists a clinically proven anti-VEGF therapy.
- Harrow secured exclusive U.S. commercialization rights for BYOOVIZ and OPUVIZ® (aflibercept-yszy) through a partnership with Samsung Bioepis.
- The $9 billion U.S. anti-VEGF market is rapidly growing, driven by increasing demand for retinal disease therapies.
The big picture
Harrow's launch of BYOOVIZ underscores the growing importance of biosimilars in the ophthalmology sector, particularly for retinal diseases. The company is positioning itself as a key player in the $9 billion anti-VEGF market by leveraging exclusive commercialization rights and a strong portfolio of retina-focused products. This move aligns with broader industry trends toward cost-effective, clinically proven therapies that address sight-threatening conditions.
What we're watching
- Market Penetration
- How quickly BYOOVIZ will gain market share against established anti-VEGF therapies like LUCENTIS and EYLEA.
- Regulatory Dynamics
- Whether the interchangeability designation of BYOOVIZ will drive broader adoption among retina specialists.
- Portfolio Strategy
- The pace at which Harrow can integrate and commercialize both BYOOVIZ and OPUVIZ to strengthen its retina franchise.